The global clinical next-generation sequencing (NGS) data analysis market enjoys a valuation of US$ 2.3 Billion in 2023, and it is further projected to expand at a CAGR of 17.4% over the forecasted years. According to a recent study by Future Market Insights, NGS data analysis & sequencing services are leading the market with a share of about 41.8% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2023 | US$ 2.3 Billion |
| Market Value 2033 | US$ 13.1 Billion |
| CAGR 2023 to 2033 | 17.4% |
| Market Share of Top 5 Countries | 66.0% |
| Key Market Players | Agilent Technologies, Inc., Illumina, Inc., Thermo Fisher Scientific, Inc., Eurofins Scientific, BGI Group, Qiagen, Roche Diagnostics, DNA Star, Inc., Bio-Rad Laboratories, Inc., Congenica Ltd., Theragen Etex Inc., PerkinElmer, Inc., Partek Inc., Oxford Nanopore Technologies PLC., Pacific Biosciences of California, Inc., Golden Helix, Inc., and BioDatomics. |
In order to determine DNA/RNA sequences for the complete genome or to examine a particular region of interest connected to diseases or biological processes, a breakthrough method called next-generation sequencing is being developed. The market for clinical next-generation sequencing data analysis has expanded because of the demand for comprehensive information on genomic sequences.
The nucleotide sequence of entire genomes or specific portions of DNA or RNA can be ascertained using NGS data analysis tools. Sequence alignment, alignment visualisation, gene prediction, and variation analysis tools are a few of the NGS data analysis tools.
With its extremely high throughput, scalability and speed, next-generation sequencing (NGS) is a massively parallel sequencing technology. The sequencers utilised in the sequencing process are known as next-generation sequencing platforms. The NGS platforms contribute to the vast scale delivery of exceptionally high data quality and accuracy.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global sales of the market are anticipated to rise at a CAGR of 11.9% between 2014 and 2022, owing to the rising prevalence of various chronic diseases.
The global market holds around 39.2% share of the overall global DNA sequencing market with a value of around US$ 5.8 Billion, in 2022.
One of the key factors propelling growth of the market in the coming years is the increasing number of life sciences companies. With the expansion of the life sciences industry, numerous small and medium-sized companies are entering the market with novel product offerings and more complex technology to set themselves apart from competitors. Companies conduct extensive research in order to provide novel products.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around US$ 13.1 billion during the year 2033.
Technological advances in genomic-based bioinformatics tools are providing many opportunities for market growth. A sizable amount of genetic data is now accessible on web-based bioinformatics platforms because of recent advancements in bioinformatics research and technologies.
Research analysts or data scientists can now compare and assess the quality of their sequencing run, assess in-line control validation, assign sequences to known regions, and characterise other sequences that reflect certain immune receptor clones.
One can infer information about unique immune response traits, their associated current illness scenario, and the consequences of therapeutic antigen presentation by understanding the abundance of particular clones and how they fluctuate in relation to treatment response and disease progression.
Performing tests on relatively tiny samples allows for efficient analysis from easily available material without the need for extra sampling, which is another benefit of genomic-based analyses.
For instance, Illumina released a BaseSpace Informatics Suite in 2014 that enables a lab to follow genetic tests even if it has no genomic computing infrastructure of its own. The suite's extensive software library makes it simple to carry out ordinary data analysis of sequences.
Principal Consultant
In undeveloped countries, there is less access to modern infrastructure. Therefore, the only alternative for using these technologies to carry out immune repertoire sequencing experiments is outsourcing. Additionally, some outsourcing companies in poor countries are known for offering inferior services.
To be precise, these companies do not actually offer the sequencing service. Instead, they serve as local service providers for companies with operations abroad. They submit samples to companies in other countries for sequencing, and then they get the results. Poor service delivery occurs during the transit and sequence process time due to a number of variables, including inappropriate sample handling, transportation issues, and lengthy wait periods.
Overall, the process is quite costly, takes a long time, and often takes several months to provide the desired outcomes. Therefore, low quality of outsourcing services is likely to limit the overall market growth.
The USA dominates the North American region with a total market share of around 89.1% in 2022 and is expected to continue to experience the same growth throughout the forecast period. The regional dominance is attributed to increasing cancer cases in the region. For instance, according to American Cancer Society, in 2022, 1.9 million new cancer cases were diagnosed and around 609,360-cancer related deaths in the United States were estimated.
Various FDA approvals and rapid technological developments have helped in the growth of this region.
Germany held a market share of around 32.1% in 2022 in the European clinical next-generation sequencing (NGS) data analysis market, owing to increasing collaboration, acquisition, and mergers by the market players in the region. For instance, in April 2022, Illumina and Hannover Medical School signed a contract to evaluate the use of rapid whole-genome sequencing in critically ill kids who are thought to have a hereditary or uncommon condition.
Also, the region is heavily focused on research and developments in the pharmaceutical industry, biotechnological industry, and novel technological developments, which is boosting the market for clinical next-generation sequencing (NGS) data analysis.
China holds a market share of 56.3%, with a market value of US$ 107.7 Million in the East Asia clinical next-generation sequencing (NGS) data analysis market in 2022. Increasing prevalence of autism a disorder that causes substantial distress is the main factor stimulating the regional market. For instance, according to NHC Study Team. Prevalence of Autism Spectrum Disorder in China: A Nationwide Multi-center Population-based Study among Children Aged 6 to 12 Years. Neurosci Bull. 2020, out of 142,086 around 363 children were confirmed having autism spectrum disorder.
Disruptive variations in the genome's protein-coding regions can be found with next-generation sequencing (NGS). These NGS techniques changed the search for the ASD gene in conjunction with big cohorts and new statistical techniques. In order to understand the neurobiological effects of altering these ASD-associated genes, functional genetic data, such as gene expression, is greatly benefited from the use of NGS techniques.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
NGS data analysis & sequencing services are expected to give high growth at a CAGR of 15.2% between 2023 and 2033. This is because services for NGS data analysis are readily available and reasonably priced. For companies with inadequate infrastructure, this service offers management and interpretation support.
For instance, ArrayGen Technologies provides a broad range of NGS data processing services in the fields of cancer genomics, crop biotechnology, personalised medicine, and disease association research. A comparable selection of NGS data analysis services is offered by ThermoFisher Scientific. The segment growth is attributable to the readily accessible, reasonably priced NGS data analysis services.
Sequencing by synthesis (SBS) is widely adopted with the market share of 42.7% in the global market in 2022. DNA polymerases and dNTPs are employed to replicate (or synthesise) the strand that has to be sequenced in the sequencing by synthesis technique.
De novo sequencing, long-insert paired-end reads for fast sequence assembly, and other applications are provided by SBS technology as well as to short-insert coupled reads for high-resolution genomic studies. Combining short inserts with long reads improves the ability to fully characterise any genome. The segment increase is attributable to SBS's affirmative technology elements.
Medical research in global clinical next-generation sequencing data analysis market is widely used, holding a market share of 39.6% in the global market in 2022. This segment is predicted to increase significantly because of the use of NGS for the study of tumour heterogeneity, the identification of new genes connected to cancer, and the finding of changes related to carcinogenesis.
The Genomic Medicine Service of the National Health Service in the United Kingdom has adopted a sequencing-based method for the clinical investigation of cancer with an unknown cause and the evaluation of potential treatments. Increase in such sequencing-based approaches for various research is anticipated to boost the segment growth.
Academic institutes & research centres hold a market share of 37.7% during the year 2022. Increasing adoption of NGS software platforms the factors attributed for segment growth. Several academic and research organisations now use more NGS software platforms for their projects requiring data interpretation because of falling NGS technology costs.
A further factor that is expected to promote income production in this sector is the gradual increase in the number of qualified employees handling software and computational tools in research institutions. Several institutions provide on-site bioinformatics training programmes and courses with the goal of improving knowledge of various sequencing data analysis options.
Major manufacturers are striving to increase the market reach of both their key products and the solutions they offer to consumers. For instance, today's top manufacturers often offer specialised solutions based on the needs of different end users. Due to the high level of competition in the market, many top competitors are heavily concentrating on various market consolidation operations like merger, acquisition, supply distribution partnerships, and the introduction of new products.
Instances of important developmental strategies used among market participants in the clinical next-generation sequencing (NGS) data analysis market are presented below:
Similarly, the team at Future Market Insights has tracked recent developments related to companies within the clinical next-generation sequencing (NGS) data analysis space. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2014 to 2022 |
| Forecast Data | 2023 to 2033 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa |
| Key Countries Covered | The USA, Canada, Brazil, Mexico, Argentina, The United Kingdom, Germany, Italy, Russia, Spain, France, Benelux, Nordics Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa and South Africa |
| Key Market Segments Covered | Solution and Services, Technology, Application, End User, and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global clinical next-generation sequencing (NGS) data analysis market value was US$ 2.3 billion in 2022.
In 2022, the revenue generated from sales to academic institutes and research centre was 37.7% of the total.
The China market was valued at US$ 107.7 million that is 56.3% of the global market in 2022.
NGS data analysis & sequencing services segment is forecasted to grow at 15.2% CAGR through 2033.
Sequencing by synthesis (SBS) technology is widely adopted and had 42.7% market share in 2022.
1. Executive Summary | Clinical Next-Generation Sequencing (NGS) Data Analysis Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply–Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends
3.3. Regional Trends
4. Key Success Factors
4.1. NGS Data Analysis Tools Adoption and Usage Analysis
4.2. Key Promotional Strategies by Manufacturers
4.3. Regulatory Landscape
4.4. PESTLE Analysis
4.5. Porter’s Analysis
4.6. Reimbursement Scenario
5. Market Background
5.1. Macro–Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.1.3. Global DNA Sequencing Market Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Technological Advancement in NGS Sequencing Tools
5.2.2. Growing Innovations and Wide Industry Scope
5.2.3. Significant Developments in the Research and Biotechnology Space
5.2.4. Investments by Various Local Players
5.2.5. Adoption Rate of NGS Sequencing Services
5.2.6. Key Players’ Historic Growth
5.2.7. Growing Healthcare Expenditure
5.2.8. Regulatory Scenario
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity
6. COVID–19 Crisis – Impact Assessment
6.1. Impact of COVID–19: An Overview
6.2. COVID–19 and Impact Analysis
6.2.1. By Solution and Services
6.2.2. By Technology
6.2.3. By Application
6.2.4. By End User
6.2.5. By Region
6.3. 2022 Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2014 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2014 to 2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
7.2.1. Y–o–Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Solution and Services
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Solution and Services, 2014 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Solution and Services, 2023 to 2033
8.3.1. NGS Data Analysis Tools
8.3.1.1. Sequence Alignment Tools
8.3.1.2. Alignment Visualization Tools
8.3.1.3. Gene Prediction Tools
8.3.1.4. Variant Analysis Tools
8.3.1.5. Others
8.3.2. Platforms
8.3.2.1. Next–Generation Sequencing (NGS) Platforms
8.3.2.2. Clinical Informatics Platforms
8.3.2.3. Others
8.3.3. NGS Data Analysis & Sequencing Services
8.3.3.1. Whole–Genome Sequencing (WGS)
8.3.3.2. Whole Exome Sequencing (WES)
8.3.3.3. Comprehensive genomic profiling (CGP)
8.3.3.4. Custom Panels
8.3.3.5. RNA Sequencing
8.3.3.6. Other Sequencing Services
8.3.4. NGS Storage, Management & Cloud Computing Platform
8.4. Market Attractiveness Analysis By Solution and Services
9. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Technology
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) By Technology, 2014 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Technology, 2023 to 2033
9.3.1. Sequencing by Synthesis (SBS)
9.3.2. Nanopore Sequencing
9.3.3. Single–Molecule Real–Time (SMRT) Sequencing
9.3.4. Others
9.4. Market Attractiveness Analysis By Technology
10. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) By Application, 2014 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033
10.3.1. Diagnostics
10.3.2. Drug Discovery & Designing
10.3.3. Medical Research
10.3.4. Others
10.4. Market Attractiveness Analysis By Application
11. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) By End User, 2014 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
11.3.1. Hospitals & Clinics
11.3.2. Academic Institutes & Research Centres
11.3.3. Biotechnology Companies
11.3.4. Life Science Technology Vendors
11.3.5. Others
11.4. Market Attractiveness Analysis By End User
12. Global Market Analysis 2014 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2014 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2014 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Solution and Services
13.3.3. By Technology
13.3.4. By Application
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Solution and Services
13.4.3. By Technology
13.4.4. By Application
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints – Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Solution and Services
13.8.1.2.2. By Technology
13.8.1.2.3. By Application
13.8.1.2.4. By End User
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Solution and Services
13.8.2.2.2. By Technology
13.8.2.2.3. By Application
13.8.2.2.4. By End User
14. Latin America Market Analysis 2014 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Solution and Services
14.3.3. By Technology
14.3.4. By Application
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Solution and Services
14.4.3. By Technology
14.4.4. By Application
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints – Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Solution and Services
14.8.1.2.2. By Technology
14.8.1.2.3. By Application
14.8.1.2.4. By End User
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Solution and Services
14.8.2.2.2. By Technology
14.8.2.2.3. By Application
14.8.2.2.4. By End User
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Solution and Services
14.8.3.2.2. By Technology
14.8.3.2.3. By Application
14.8.3.2.4. By End User
15. Europe Market Analysis 2014 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. United Kingdom
15.3.1.2. Germany
15.3.1.3. France
15.3.1.4. Italy
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Solution and Services
15.3.3. By Technology
15.3.4. By Application
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Solution and Services
15.4.3. By Technology
15.4.4. By Application
15.4.5. By End User
15.5. Key Market Participants – Intensity Mapping
15.6. Drivers and Restraints – Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. U.K. Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Solution and Services
15.7.1.2.2. By Technology
15.7.1.2.3. By Application
15.7.1.2.4. By End User
15.7.2. Germany Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Solution and Services
15.7.2.2.2. By Technology
15.7.2.2.3. By Application
15.7.2.2.4. By End User
15.7.3. France Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Solution and Services
15.7.3.2.2. By Technology
15.7.3.2.3. By Application
15.7.3.2.4. By End User
15.7.4. Italy Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Solution and Services
15.7.4.2.2. By Technology
15.7.4.2.3. By Application
15.7.4.2.4. By End User
15.7.5. Spain Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Solution and Services
15.7.5.2.2. By Technology
15.7.5.2.3. By Application
15.7.5.2.4. By End User
15.7.6. BENELUX Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Solution and Services
15.7.6.2.2. By Technology
15.7.6.2.3. By Application
15.7.6.2.4. By End User
15.7.7. Nordic Countries Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Solution and Services
15.7.7.2.2. By Technology
15.7.7.2.3. By Application
15.7.7.2.4. By End User
15.7.8. Russia Market Analysis
15.7.8.1. Introduction
15.7.8.2. Market Analysis and Forecast by Market Taxonomy
15.7.8.2.1. By Solution and Services
15.7.8.2.2. By Technology
15.7.8.2.3. By Application
15.7.8.2.4. By End User
16. East Asia Market Analysis 2014 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Solution and Services
16.3.3. By Technology
16.3.4. By Application
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Solution and Services
16.4.3. By Technology
16.4.4. By Application
16.4.5. By End User
16.5. Key Market Participants – Intensity Mapping
16.6. Drivers and Restraints – Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. China Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Solution and Services
16.7.1.2.2. By Technology
16.7.1.2.3. By Application
16.7.1.2.4. By End User
16.7.2. Japan Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Solution and Services
16.7.2.2.2. By Technology
16.7.2.2.3. By Application
16.7.2.2.4. By End User
16.7.3. South Korea Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Solution and Services
16.7.3.2.2. By Technology
16.7.3.2.3. By Application
16.7.3.2.4. By End User
17. South Asia Market Analysis 2014 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Malaysia
17.3.1.3. Thailand
17.3.1.4. Indonesia
17.3.1.5. Rest of South Asia
17.3.2. By Solution and Services
17.3.3. By Technology
17.3.4. By Application
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Solution and Services
17.4.3. By Technology
17.4.4. By Application
17.4.5. By End User
17.5. Key Market Participants – Intensity Mapping
17.6. Drivers and Restraints – Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. India Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Solution and Services
17.7.1.2.2. By Technology
17.7.1.2.3. By Application
17.7.1.2.4. By End User
17.7.2. Malaysia Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Solution and Services
17.7.2.2.2. By Technology
17.7.2.2.3. By Application
17.7.2.2.4. By End User
17.7.3. Thailand Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Solution and Services
17.7.3.2.2. By Technology
17.7.3.2.3. By Application
17.7.3.2.4. By End User
17.7.4. Indonesia Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast by Market Taxonomy
17.7.4.2.1. By Solution and Services
17.7.4.2.2. By Technology
17.7.4.2.3. By Application
17.7.4.2.4. By End User
18. Oceania Market 2014 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Solution and Services
18.3.3. By Technology
18.3.4. By Application
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Solution and Services
18.4.3. By Technology
18.4.4. By Application
18.4.5. By End User
18.5. Key Market Participants – Intensity Mapping
18.6. Drivers and Restraints – Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. Australia Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Solution and Services
18.7.1.2.2. By Technology
18.7.1.2.3. By Application
18.7.1.2.4. By End User
18.7.2. New Zealand Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Solution and Services
18.7.2.2.2. By Technology
18.7.2.2.3. By Application
18.7.2.2.4. By End User
19. Middle East and Africa (MEA) Market Analysis 2014 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis by Market Taxonomy, 2014 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. South Africa
19.3.1.4. Rest of Middle East and Africa
19.3.2. By Solution and Services
19.3.3. By Technology
19.3.4. By Application
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Solution and Services
19.4.3. By Technology
19.4.4. By Application
19.4.5. By End User
19.5. Key Market Participants – Intensity Mapping
19.6. Drivers and Restraints – Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. GCC Countries Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Solution and Services
19.7.1.2.2. By Technology
19.7.1.2.3. By Application
19.7.1.2.4. By End User
19.7.2. Türkiye Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Solution and Services
19.7.2.2.2. By Technology
19.7.2.2.3. By Application
19.7.2.2.4. By End User
19.7.3. North Africa Market Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Solution and Services
19.7.3.2.2. By Technology
19.7.3.2.3. By Application
19.7.3.2.4. By End User
19.7.4. South Africa Market Analysis
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By Solution and Services
19.7.4.2.2. By Technology
19.7.4.2.3. By Application
19.7.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players (%)
20.3. Market Presence Analysis
20.3.1. By Regional Footprint of Players
20.3.2. Product Footprint of Players
20.3.3. Channel Footprint of Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Agilent Technologies, Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Key Financials
21.3.1.4. SWOT Analysis
21.3.1.5. Key Developments
21.3.1.6. Sales Footprint
21.3.1.7. Strategy Overview
21.3.2. Illumina, Inc.
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Key Financials
21.3.2.4. SWOT Analysis
21.3.2.5. Key Developments
21.3.2.6. Sales Footprint
21.3.2.7. Strategy Overview
21.3.3. Thermo Fisher Scientific, Inc.
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Key Financials
21.3.3.4. SWOT Analysis
21.3.3.5. Key Developments
21.3.3.6. Sales Footprint
21.3.3.7. Strategy Overview
21.3.4. Eurofins Scientific
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Key Financials
21.3.4.4. SWOT Analysis
21.3.4.5. Key Developments
21.3.4.6. Sales Footprint
21.3.4.7. Strategy Overview
21.3.5. BGI Group
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Key Financials
21.3.5.4. SWOT Analysis
21.3.5.5. Key Developments
21.3.5.6. Sales Footprint
21.3.5.7. Strategy Overview
21.3.6. Qiagen
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Key Financials
21.3.6.4. SWOT Analysis
21.3.6.5. Key Developments
21.3.6.6. Sales Footprint
21.3.6.7. Strategy Overview
21.3.7. Roche Diagnostics
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Key Financials
21.3.7.4. SWOT Analysis
21.3.7.5. Key Developments
21.3.7.6. Sales Footprint
21.3.7.7. Strategy Overview
21.3.8. DNAStar, Inc.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Key Financials
21.3.8.4. SWOT Analysis
21.3.8.5. Key Developments
21.3.8.6. Sales Footprint
21.3.8.7. Strategy Overview
21.3.9. Bio–Rad Laboratories, Inc.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Key Financials
21.3.9.4. SWOT Analysis
21.3.9.5. Key Developments
21.3.9.6. Sales Footprint
21.3.9.7. Strategy Overview
21.3.10. Congenica Ltd.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Key Financials
21.3.10.4. SWOT Analysis
21.3.10.5. Key Developments
21.3.10.6. Sales Footprint
21.3.10.7. Strategy Overview
21.3.11. Theragen Etex Inc.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Key Financials
21.3.11.4. SWOT Analysis
21.3.11.5. Key Developments
21.3.11.6. Sales Footprint
21.3.11.7. Strategy Overview
21.3.12. PerkinElmer, Inc.
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Key Financials
21.3.12.4. SWOT Analysis
21.3.12.5. Key Developments
21.3.12.6. Sales Footprint
21.3.12.7. Strategy Overview
21.3.13. Partek Inc.
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Key Financials
21.3.13.4. SWOT Analysis
21.3.13.5. Key Developments
21.3.13.6. Sales Footprint
21.3.13.7. Strategy Overview
21.3.14. Oxford Nanopore Technologies PLC.
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Key Financials
21.3.14.4. SWOT Analysis
21.3.14.5. Key Developments
21.3.14.6. Sales Footprint
21.3.14.7. Strategy Overview
21.3.15. Pacific Biosciences of California, Inc.
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. Key Financials
21.3.15.4. SWOT Analysis
21.3.15.5. Key Developments
21.3.15.6. Sales Footprint
21.3.15.7. Strategy Overview
21.3.16. Golden Helix, Inc.
21.3.16.1. Overview
21.3.16.2. Product Portfolio
21.3.16.3. Key Financials
21.3.16.4. SWOT Analysis
21.3.16.5. Key Developments
21.3.16.6. Sales Footprint
21.3.16.7. Strategy Overview
21.3.17. BioDatomics
21.3.17.1. Overview
21.3.17.2. Product Portfolio
21.3.17.3. Key Financials
21.3.17.4. SWOT Analysis
21.3.17.5. Key Developments
21.3.17.6. Sales Footprint
21.3.17.7. Strategy Overview
21.3.18. PierianDx
21.3.18.1. Overview
21.3.18.2. Product Portfolio
21.3.18.3. Key Financials
21.3.18.4. SWOT Analysis
21.3.18.5. Key Developments
21.3.18.6. Sales Footprint
21.3.18.7. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Clinical Next-Generation Sequencing (NGS) Data Analysis Market
